

# Results of the inquiry of the Society for Medicinal Plant Research

# "Biological and Biochemical Contents of Study Courses in Pharmaceutical Biology/ Pharmacognosy"



# Study design:

- Period: November 1999 January 2000
- <u>Target group</u>:

university teachers and staff

(GA members) all over Europe

and Turkey

- 300 questionnaires sent out
- 126 questionnaires returned (42%)



# Study design:

7 main categories:

- **BIOLOGY FOR PHARMACISTS**
- GENERAL BIOCHEMISTRY (interdisciplinary)
- MICROBIOLOGY
- DRUGS OF BIOLOGICAL (NATURAL) ORIGIN
- PHYTOPHARMACEUTICALS (herbal medicinal products)
- QUALITY ASSURANCE OF DRUGS OF NATURAL ORIGIN
- FURTHER SUBJECTS

## with a total of 56 subcategories



**Questionnaire (1):** 

#### Questionnaire on the Curriculum of Pharmaceutical Biology/Pharmacognosy in Europe

Pharmacy is included in the process of harmonising Higher Education Studies in Europe. In order to prepare a statement on the current status and on future perspectives of Pharmacognosy/ Pharmaceutical Biology education in Europe, the Society for Medicinal Plant Research (**GA**) wants to evaluate the contents of theoretical and practical courses by Pharmacognosy/ Pharmaceutical Biology groups and departments in Europe.

The following questionnaire will help us to learn which of the contents are considered to be part of the material taught in Pharmacognosy/ Pharmaceutical Biology in the different European countries and schools of Pharmacy and how their importance is rated for the future. The interrogated persons were asked for details on:

#### • Present situation:

Subjects are taught at the college/university/ institute at present: yes or no.

#### • Teaching method:

Methods used to teach the subject matter (if it applies)

- L by lectures and seminars
- **P** by laboratory classes, excursions, other practical training

#### • Future importance:

Considerations for the importance of the subject in future as follows:

#### 1 Absolutely necessary

- 2 Important
- 3 Optional
- 4 Unnecessary

At the end of the table there was some space for individual suggestions.



# Questionnaire (2):

### BIOLOGICAL AND BIOCHEMICAL CONTENTS of Study

Courses in Pharmaceutical Biology/ Pharmacognosy (based on the Committee for Pharmaceutical Education) of the European Commission XV/E/8341/6/93 of 26-7-95.

## **BIOLOGY FOR PHARMACISTS**

| BIO1 | Principles of cytology, basic cell structure and organization |  |
|------|---|--|
|      | (Pro- and eukaryotes, plant and animal cells )                |  |
| BIO2 | Principles of histology (plant and animal tissue)             |  |
| BIO3 | Principles of anatomy and morphology of plants and animals    |  |
| BIO4 | Principles of systematics of pharmaceutically and medically   |  |
|      | important taxa of viruses, microorganisms, fungi, plants      |  |
| BIO5 | Principles of physiology (plants and mammals)                 |  |
| BIO6 | Principles of ecology   |  |
| BIO7 | Principles of genetics  |  |



# **Questionnaire (3):**

## GENERAL BIOCHEMISTRY (interdisciplinary)

| BIOCH1  | Proteins, peptides and amino acids, protein biosynthesis;      |  |
|---------|--|--|
|         | metabolism of proteins   |  |
| BIOCH2  | Enzymes and coenzymes  |  |
| BIOCH3  | Nucleic acids, transcription, replication, translation         |  |
| BIOCH4  | Porphyrins (haemoglobin, chlorophyll)                          |  |
| BIOCH5  | Biological oxidation (metabolism of oxygen)                    |  |
| BIOCH6  | Respiration and citric acid cycle                              |  |
| BIOCH7  | Simple lipids and lipid metabolism                             |  |
| BIOCH8  | Complex lipids, phospholipids, glycolipids and membrane        |  |
|         | structures   |  |
| BIOCH9  | Isoprenoids (steroids, carotenoids)                            |  |
| BIOCH10 | Sugars (glycolysis, alcohol, fermentation, metabolism, aerobic |  |
|         | carbohydrate decomposition, gluconeogenesis), Glycosides       |  |
| BIOCH11 | Photosynthesis   |  |
| BIOCH12 | Metabolic pathways (regulation of metabolism)                  |  |
| BIOCH13 | Inorganic metabolism, water regulation                         |  |
| BIOCH14 | Nutrition, vitamins  |  |
| BIOCH15 | Specific biochemical functions of some organs                  |  |



**Questionnaire (4):** 

# MICROBIOLOGY

| MICBIO1 | General morphological and physiological basic aspects of             |  |
|---------|--|--|
|         | microorganisms, industrial significance                              |  |
| MICBIO2 | Practical microbiology (nutrient media, sterilization, safety        |  |
|         | protocols), staining techniques, identification, counting,           |  |
|         | classical and modern methods in microbiology                         |  |
| MICBIO3 | Special techniques (antibiotic assays, sterility tests, detection of |  |
|         | endotoxins, disinfection and preservation)                           |  |
| MICBIO4 | Introduction to hygienics (hygienic working, cleaning and            |  |
|         | disinfection, CIP, SIP, hygiene protocols, GMP, HACCP)               |  |



# **Questionnaire (5):**

## DRUGS OF BIOLOGICAL (NATURAL) ORIGIN

| DRUG1  | Medicinal plants, crude drugs, preparations (parent plants,  |  |  |
|--------|--|--|--|
|        | cultivation and harvesting, secondary metabolites, active    |  |  |
|        | principles, mode of actions)                                 |  |  |
| DRUG2  | Pharmaceutically used secondary plant metabolites (including |  |  |
|        | essential oils, gums)  |  |  |
| DRUG3  | Pharmaceutically used primary plant metabolites              |  |  |
| DRUG4  | Natural addictive toxins and their sources, drugs of         |  |  |
|        | abuse/addiction of plant origin                              |  |  |
| DRUG5  | Antibiotics and biological cytostatics (sources, production, |  |  |
|        | mode of action, therapeutic uses, mechanisms of resistance   |  |  |
|        | and transmission)  |  |  |
| DRUG6  | Microbes used as drugs ( eg. <i>S. cerevisiae, E. coli</i> , |  |  |
|        | Lactobacillus, yeast products, etc)                          |  |  |
| DRUG7  | Drugs produced by biotechnology                              |  |  |
| DRUG8  | Enzymes, vitamins and hormones, including activation and     |  |  |
|        | inhibition of biological processes                           |  |  |
| DRUG9  | Blood products   |  |  |
| DRUG10 | Biotechnology (Production and processing of biologically-    |  |  |
|        | derived pharmaceuticals)                                     |  |  |
| DRUG11 | Isolation of natural products (strategies, methods)          |  |  |
| DRUG12 | Biosynthesis of plant and microbial constituents             |  |  |



# **Questionnaire (6):**

## PHYTOPHARMACEUTICALS (HERBAL MEDICINAL PRODUCTS)

| ΡΗΥΤΟ1 | Quality, activity, efficacy, adverse effects |
|--------|--|
| ΡΗΥΤΟ2 | Therapeutic uses                             |

## QUALITY ASSURANCE OF DRUGS OF NATURAL ORIGIN

| QUAL1 | Identification and quality assessment of plant-derived drugs and preparations  |
|-------|--|
| QUAL2 | Analytical procedures for investigation and standardization of<br>herbal medicinal products and other preparations of biological<br>origin |



# **Questionnaire (7):** FURTHER SUBJECTS

| SUB1  | Cultivation and collection of medicinal plants             |  |  |
|-------|--|--|--|
| SUB2  | Cell and tissue culture (plant and animal cells)           |  |  |
| SUB3  | Principles of immunology                                   |  |  |
| SUB4  | Application of immunological and enzymatic methods in      |  |  |
|       | analysis, diagnostics and therapy                          |  |  |
| SUB5  | Vaccination products, immunoglobulins and immune sera      |  |  |
|       | (production, assay and use)                                |  |  |
| SUB6  | Molecular biology (including molecular biology techniques) |  |  |
| SUB7  | Gene technology, gene technology for production of         |  |  |
|       | pharmaceuticals  |  |  |
| SUB8  | Poisonous plants and fungi (phytotoxicology)               |  |  |
| SUB9  | Alternative therapies based on biological remedies or      |  |  |
|       | ethnopharmacognosy   |  |  |
| SUB10 | Health food and dietary supplements                        |  |  |

## **OTHER SUBJECTS**

| SUB11 | Gene expression and regulation   |
|-------|--|
| SUB12 | Regulation of cell cycle, cell division, cell and tissue differentiation |
| SUB13 | Gene therapy   |
| SUB14 | Viruses, oncogenes and cancer  |



# CONTRIBUTIONS: WESTERN EUROPE

|             | n  | %  |
|-------------|----|----|
| Austria     | 8  | 6  |
| Belgium     | 9  | 7  |
| England     | 9  | 7  |
| France      | 6  | 5  |
| Germany     | 25 | 20 |
| Greece      | 1  | 1  |
| Ireland     | 1  | 1  |
| Italy       | 5  | 4  |
| Netherlands | 1  | 1  |
| Norway      | 1  | 1  |
| Portugal    | 6  | 5  |
| Spain       | 12 | 10 |
| Switzerland | 4  | 3  |

## **Total questionnaires: 88**




# CONTRIBUTIONS: CENTRAL AND EASTERN EUROPE

|                | n  | % |
|----------------|----|---|
| Bulgaria       | 1  | 1 |
| Croatia        | 2  | 2 |
| Czech Republic | 7  | 6 |
| Hungary        | 1  | 1 |
| Macedonia      | 1  | 1 |
| Poland         | 11 | 9 |
| Romania        | 4  | 3 |
| Serbia         | 1  | 1 |
| Slowakia       | 5  | 4 |
| Turkey         | 5  | 4 |

## **Total questionnaires: 38**




### **BIOLOGY - Present situation**



B. Kopp, Ch. Wawrosch, Institute of Pharmacognosy, University of Vienna




#### **BIOLOGY - Lecture**



B. Kopp, Ch. Wawrosch, Institute of Pharmacognosy, University of Vienna




#### **BIOLOGY - Practical**



B. Kopp, Ch. Wawrosch, Institute of Pharmacognosy, University of Vienna




#### **BIOLOGY - Future**











B. Kopp, Ch. Wawrosch, Institute of Pharmacognosy, University of Vienna





B. Kopp, Ch. Wawrosch, Institute of Pharmacognosy, University of Vienna






B. Kopp, Ch. Wawrosch, Institute of Pharmacognosy, University of Vienna




**GENERAL BIOCHEMISTRY - Lecture (1)** 






**GENERAL BIOCHEMISTRY - Lecture (2)** 






**GENERAL BIOCHEMISTRY - Lecture (3)** 






### **GENERAL BIOCHEMISTRY - Practical (1)**






### **GENERAL BIOCHEMISTRY - Practical (2)**



B. Kopp, Ch. Wawrosch, Institute of Pharmacognosy, University of Vienna




### **GENERAL BIOCHEMISTRY - Practical (3)**






**GENERAL BIOCHEMISTRY - Future 1** 






**GENERAL BIOCHEMISTRY - Future 2** 



B. Kopp, Ch. Wawrosch, Institute of Pharmacognosy, University of Vienna




**GENERAL BIOCHEMISTRY - Future 3** 






**MICROBIOLOGY - Present situation** 






#### **MICROBIOLOGY - Lecture**






### **MICROBIOLOGY - Practical**






### **MICROBIOLOGY - Future**






## DRUGS OF BIOL. ORIGIN - Present situation (1)






## DRUGS OF BIOL. ORIGIN - Present situation (2)



B. Kopp, Ch. Wawrosch, Institute of Pharmacognosy, University of Vienna




DRUGS OF BIOL. ORIGIN - Present situation (3)



B. Kopp, Ch. Wawrosch, Institute of Pharmacognosy, University of Vienna




**DRUGS OF BIOL. ORIGIN - Lecture (1)** 






**DRUGS OF BIOL. ORIGIN - Lecture (2)** 






DRUGS OF BIOL. ORIGIN - Lecture (3)






DRUGS OF BIOL. ORIGIN - Practical (1)






DRUGS OF BIOL. ORIGIN - Practical (2)






**DRUGS OF BIOL. ORIGIN - Practical (3)** 






**DRUGS OF BIOL. ORIGIN - Future 1** 



B. Kopp, Ch. Wawrosch, Institute of Pharmacognosy, University of Vienna




**DRUGS OF BIOL. ORIGIN - Future 2** 






**DRUGS OF BIOL. ORIGIN - Future 3** 



B. Kopp, Ch. Wawrosch, Institute of Pharmacognosy, University of Vienna




# **PHYTOPHARMACEUTICALS - Present situation**






# **PHYTOPHARMACEUTICALS - Lecture**






# **PHYTOPHARMACEUTICALS - Practical**






# **PHYTOPHARMACEUTICALS - Future**






# **QUALITY ASSURANCE - Present situation**






# **QUALITY ASSURANCE - Lecture**






# **QUALITY ASSURANCE - Practical**






# **QUALITY ASSURANCE - Future**








**FURTHER SUBJECTS - Present situation (1)** 



B. Kopp, Ch. Wawrosch, Institute of Pharmacognosy, University of Vienna




**FURTHER SUBJECTS - Present situation (2)** 



B. Kopp, Ch. Wawrosch, Institute of Pharmacognosy, University of Vienna




# **FURTHER SUBJECTS - Lecture (1)**



B. Kopp, Ch. Wawrosch, Institute of Pharmacognosy, University of Vienna




# **FURTHER SUBJECTS - Lecture (2)**



B. Kopp, Ch. Wawrosch, Institute of Pharmacognosy, University of Vienna




# **FURTHER SUBJECTS - Practical (1)**



B. Kopp, Ch. Wawrosch, Institute of Pharmacognosy, University of Vienna




# **FURTHER SUBJECTS - Practical (2)**



B. Kopp, Ch. Wawrosch, Institute of Pharmacognosy, University of Vienna




# **FURTHER SUBJECTS - Future 1**






# **FURTHER SUBJECTS - Future 2**



B. Kopp, Ch. Wawrosch, Institute of Pharmacognosy, University of Vienna




**OTHER SUBJECTS - Present situation** 






# **OTHER SUBJECTS - Lecture**



B. Kopp, Ch. Wawrosch, Institute of Pharmacognosy, University of Vienna




# **OTHER SUBJECTS - Practical**



B. Kopp, Ch. Wawrosch, Institute of Pharmacognosy, University of Vienna



### **OTHER SUBJECTS - Future**



B. Kopp, Ch. Wawrosch, Institute of Pharmacognosy, University of Vienna